AtomVie Global Radiopharma and TerraPower Sign Major Supply Agreement for Actinium-225

Strategic Collaboration for Actinium-225 Supply

In a significant move for the field of radiopharmaceuticals, AtomVie Global Radiopharma (referred to as AtomVie) and TerraPower Isotopes, LLC (TPI) have announced a major supply agreement that promises to enhance the development and manufacturing of radiopharmaceuticals. This partnership focuses on the provision of actinium-225 (Ac-225), a crucial isotope that plays a vital role in targeted therapies for cancer and other diseases.

Details of the Agreement

Under the terms of the agreement, TPI will supply high-quality actinium-225, thus supporting AtomVie’s contract development and manufacturing organization (CDMO) activities. This arrangement is anticipated to add significant value to AtomVie’s clients who are working on Ac-225-based therapeutic programs. The dual goals of the partnership include strengthening the supply chain for radiopharmaceutical products and accelerating the development and commercialization of novel therapies that utilize this isotope.

The initiative comes at a critical time, as the demand for advanced cancer treatments continues to grow worldwide. By ensuring a reliable supply of Ac-225, AtomVie and TPI aim to enhance flexibility and responsiveness throughout the product development cycle. As Bruno Paquin, CEO of AtomVie, stated, “We are pleased to collaborate with TerraPower Isotopes to secure an actinium-225 supply for our clients. This strengthens our ability to meet the evolving needs of our pharmaceutical partners and supports their programs from development through to commercial supply.”

On the other hand, Scott Claunch, the president of TPI, expressed that the collaboration is pivotal in advancing the next generation of targeted radiopharmaceutical therapies. The partnership aligns TPI’s expertise in generating highly pure Ac-225 with AtomVie’s robust development and manufacturing capabilities, thereby enhancing patient outcomes through innovative treatment options.

Impact on the Industry

This supply agreement reflects a shared commitment to not only advance nuclear medicine innovation but also to expand global access to advanced radiotherapies. The collaboration will directly support early and late-stage development programs with international pharmaceutical partners, potentially facilitating various clinical and commercial projects worldwide.

Both companies believe that this partnership can lead to an expansion of treatment options that could significantly improve patient outcomes, particularly in oncology. As they work together to harness the potential of actinium-225, AtomVie and TPI are taking a significant step towards transforming cancer treatment paradigms through state-of-the-art radiopharmaceuticals.

Future Prospects

AtomVie Global Radiopharma is recognized for its leading role in contract development and manufacturing for clinical and commercial radiopharmaceutical products. With its comprehensive suite of scientific, technical, regulatory, quality, and logistics services, AtomVie serves clients globally, who are conducting clinical studies across more than 25 countries.

Looking ahead, AtomVie is set to establish a state-of-the-art facility covering 72,300 square feet, slated for completion by the end of 2025. This upgrade will bolster their capacity to produce clinical and commercial radiopharmaceuticals more efficiently, further enhancing their service offerings and technical capabilities in the market.

Similarly, TerraPower Isotopes stands at the forefront of next-generation isotope production and application, with a clear focus on advancing medical research through innovative radioisotope generators. The organization is enhancing global access to actinium-225, known for its effectiveness in targeting cancer cells while minimizing damage to surrounding healthy tissue.

In conclusion, the strategic partnership between AtomVie and TPI is poised to make a considerable impact within the realm of radiation therapy, allowing both organizations to lead the charge in medical innovation and improve the lives of patients battling severe diseases like cancer. The collaboration underscores the importance of merging expertise from different sectors to achieve common goals in healthcare advancements.